Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Exosome-loaded zinc sulphide nanoparticles therapy for psoriasis: immune regulation and skin repair by targeting IL-23/IL-17A-NF-κB pathway.

Salem NA., Mowaad NA., Elgohary R., Osman AOBS., Reda M., Kishta MS.

Animal Study on Chronic Inflammation, Immune Modulation, published in J Drug Target (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Drug Target (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42485082
DOI
10.1080/1061186X.2026.2708742

Abstract (original English)

This study investigates the therapeutic efficacy of zinc sulphide nanoparticles (ZnS NPs) encapsulated within adipose-derived mesenchymal stem cell exosomes (EXO-ZnS NPs) in an imiquimod-induced rat model of psoriasis, aiming to combine nanotechnology and regenerative medicine for enhanced immune modulation and skin repair. Adipose mesenchymal stem cells (AD-MSCs) were cultured and characterised, exosomes were isolated and validated by flow cytometry and TEM. ZnS NPs were synthesised, confirmed by XRD and TEM, and encapsulated into exosomes. Release profiles, Clinical (PASI scoring), histopathological, inflammatory and proliferative markers as well as immunohistochemical analyses were evaluated across control, psoriasis, and treatment groups (EXO, ZnS NPs, and EXO-ZnS NPs). EXO-ZnS NPs exhibited a uniform nanosize with sustained ZnS NPs release (80.5% over 24 h). In vivo , EXO-ZnS NPs significantly attenuated psoriatic symptoms, and Severity Index scores, reduced inflammatory mediators (IL-23, IL-17a, TNF-α, MCP-1, NLRP3), mitigated oxidative stress, downregulated proliferative markers (Ki-67, MMP-9), and inhibited VEGF-mediated angiogenesis. collectively restored epidermal structure and improved skin architecture. EXO-ZnS NPs synergistically combine the regenerative and immunomodulatory effects of exosomes with the intrinsic anti-inflammatory and antioxidant activities of ZnS

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research